Prostate Adenocarcinoma, Stage I Prostate Cancer
Conditions
Brief summary
This clinical trial studies stereotactic body radiation therapy in treating patients with low- and intermediate-risk prostate cancer. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
Detailed description
PRIMARY OBJECTIVES: I. To evaluate, in terms of late toxicity, the safety of stereotactic radiation therapy using the proposed fractionation schedule. SECONDARY OBJECTIVES: I. To evaluate, in terms of acute toxicity, the safety of stereotactic radiation therapy using the proposed fractionation schedule. II. To determine stereotactic treatment efficacy through biochemical failure (Phoenix criteria). III. To determine the protocol completion rate. IV. To describe patient-reported outcomes using International Index of Erectile Function (IIEF) and EPIC Urinary and Bowel Assessment questionnaires. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients undergo standard daily fractions of stereotactic body radiation therapy (SBRT) over 7-8.5 weeks.
Interventions
RADIATIONstereotactic body radiation therapy
Undergo SBRT
RADIATIONfour fraction split-course SBRT
four fraction split-course SBRT
Sponsors
Virginia Commonwealth University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have low or intermediate risk adenocarcinoma of the prostate as defined by: * Low-risk disease - Histopathology score (Gleason sum): =\<6, T-stage (per current AJCC staging criteria): T1c-T2a, and PSA: \<10 * Intermediate-risk disease as either: * Histopathology score (Gleason sum) =\< 6, T-stage (per current American Joint Committee on Cancer \[AJCC\] staging criteria): T1c-T2a, and prostate-specific antigen (PSA) \> 10 but =\< 20; or * Histopathology score (Gleason sum) 7 with =\< 50% of any cores positive, T-stage (per current AJCC staging criteria): T1c-T2a, and PSA \< 10 * Charlson index of comorbidity score =\< 4 * Ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
* Patients with history of inflammatory bowel disease, or who require steroid or cytotoxic therapy for collagen vascular disease * Patients with a history of cancer other than skin cancer within 5 years of the initiation of protocol treatment * Patients with a history of pelvic irradiation for any reason * Life expectancy \< 10 years - Prior treatment with an anti-androgen, luteinizing hormone-releasing hormone (LHRH) agonist, or a combination of the two * Prior radiation therapy, brachytherapy, or cryotherapy * Prior surgical procedure involving peri-rectal and peri-prostatic area
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Late toxicity greater than or equal to grade 2 as defined by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 criteria | 2 years | Will be tested using a continuity corrected chi-square test |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Biochemical failure as defined by the Phoenix definition | Up to 5 years | — |
| Protocol completion rate | Up to 5 years | The portion of patients completing the planned protocol with no unacceptable protocol violations is anticipated to be greater than 90%. A completion rate of 70% is deemed unacceptably low. |
| Patient-reported outcomes | Up to 5 years | International Index of Erectile Function (IIEF) and Expanded Prostate Cancer Index Composite urinary Assessment (EPIC) urinary and bowel assessments will be used to collect patient-reported outcomes. * IIEF is a widely used instrument for the evaluation of male sexual function. It is has been recommended as tool for clinical trials of erectile dysfunction and for diagnostic evaluation of erectile dysfunction severity. 15 questions 1=very low (worst) to 5=very high (best). * The EPIC urinary and bowel assessments are comprehensive instruments designed to evaluate urinary and bowel symptoms, thereby providing a unique tool for assessment of quality of life issues important in prostate cancer management. 9 questions 0=no problem to 5=big problem |
| Acute toxicity greater than or equal to grade 2 as defined by the CTCAE version 4 criteria | Up to 90 days | — |
Countries
United States
Outcome results
None listed